Status:

COMPLETED

Metabolic, Functional and Nutritional Responses to Weight Cycling in Athletes: The WAVE Study

Lead Sponsor:

University Hospital, Clermont-Ferrand

Collaborating Sponsors:

Laboratoire AME2P

Université de Fribourg, Department of Endocrinology, Metabolism and Cardiovascular System

Conditions:

Athletes

Eligibility:

All Genders

18-35 years

Phase:

NA

Brief Summary

Many elite athletes are submitted to frequent rapid weight loss periods to meet their competition weight category and then experience weight cycling (lowing and gaining weight regularly). This weight ...

Detailed Description

After an inclusion visit to ensure the eligibility of athletes to complete the entire study, each subject will perform 3 experimental sessions of 2 visits each : i) two visits during a period of maint...

Eligibility Criteria

Inclusion

  • Subjects aged 18 to 35 (inclusive),
  • exercising at least 4 sessions of endurance or weight-based sporting activities per week for a performance objective,
  • having variations of at least 5% of their weight body during the last 3 sporting seasons (a sporting season corresponds to a year during which alternates the periods of training, recovery and participation in official competitions).
  • Subject capable of providing informed consent to participate
  • Subject with a social security insurance.

Exclusion

  • Medical or surgical history deemed by the investigator to be incompatible with the study.
  • Presence of chronic pathology.
  • Disorders of eating behavior.
  • Subjects born very prematurely defined as a pregnancy inferior to 28 weeks.
  • Subjects having used a treatment for a small stature (eg growth hormone).
  • For women: irregular menstruation (changes in menstrual cycles ≥ 6 days).
  • Sports subjects with a stable weight during the last three sporting seasons (weight variation \<5%).
  • Take medication that can change body temperature.
  • Pregnant or lactating women.
  • Subjects with gastrointestinal complications and / or contraindications to ingestion of the capsule (eg diverticulosis, inflammatory bowel disease, gastrointestinal surgery ...).
  • Subjects needing MRI during ingestion of the capsule or having a pacemaker or other implanted electro-medical device.
  • Person under guardianship or not subject to a social security scheme.
  • Refusal to sign the information and consent leaflet.
  • Refusal of participation

Key Trial Info

Start Date :

May 3 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 12 2023

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT04107545

Start Date

May 3 2021

End Date

December 12 2023

Last Update

March 8 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Chu Clermont Ferrand

Clermont-Ferrand, France, 63003